



Host-pathogen interactions in typhoid fever: the model is the message

Verónica Urdaneta, Josep Casadesús

Departamento de Genética, Facultad de Biología, Universidad de Sevilla, Sevilla, Spain

Correspondence to: Josep Casadesús. Departamento de Genética, Facultad de Biología, Universidad de Sevilla, Apartado 1095, 41080 Sevilla, Spain.

Email: casadesus@us.es.

Comment on: Nickerson KP, Senger S, Zhang Y, *et al.* Salmonella Typhi Colonization Provokes Extensive Transcriptional Changes Aimed at Evading Host Mucosal Immune Defense During Early Infection of Human Intestinal Tissue. *EBioMedicine* 2018;31:92-109.

Submitted Sep 10, 2018. Accepted for publication Sep 20, 2018.

doi: [10.21037/atm.2018.09.52](https://doi.org/10.21037/atm.2018.09.52)

View this article at: <http://dx.doi.org/10.21037/atm.2018.09.52>

Salmonella enterica subspecies *enterica* is classified into serovars based on serological identification of lipopolysaccharide (O) and flagellar (H) antigens (1). Depending on the serovar and the host, *Salmonella* infection of humans has different outcomes that can be classified into two general types: (I) gastroenteritis, a self-limited infection of the terminal ileum and colon leading to diarrhea and inflammation, often caused by the broad-range serovars Typhimurium and Enteritidis; (II) typhoid fever, a systemic infection caused by the human-adapted serovars Typhi and Paratyphi. Both types of infection usually occur upon ingestion of contaminated food or water. Gastroenteritis, popularly known as salmonellosis, is confined to the intestine and rarely presents complications in healthy adults. In typhoid fever, *Salmonella* cells disseminate through the lymphatic system and within phagocytes, leading to colonization of internal organs such as the liver, the spleen, the bone marrow, and the gall bladder (2). Infection by *S. Typhi* may remain asymptomatic for 1–2 weeks, and its symptoms vary from one infected individual to another, depending on age, immune proficiency, and other factors. Common symptoms include high fever, constipation, headache, abdominal tenderness, coughing, and vomiting. Serious complications of typhoid fever are intestinal bleeding, sometimes with perforation, and typhoidal encephalopathy (2). Outbreaks of typhoid fever occur mostly in developing countries, especially in areas with a high population density, and the number of cases per year may be as high as 10–20 million worldwide, resulting in 10,000–20,000 deaths. A fraction of typhoid fever survivors (2–5%) become chronic carriers of *S. Typhi* (3). The main

niche for chronic carriage is the gall bladder, especially in patients with gallstones. A potential link between chronic carriage and hepatobiliary cancer has been considered (3,4). As a consequence of gall bladder contraction during food passage, bacterial shedding into the intestine of chronic carriers occurs, with concomitant release of *S. Typhi* into the environment.

Over several decades, studies with animal models and cell cultures have unraveled mechanisms employed by *Salmonella* serovars to cause disease in humans. A specially successful animal model has been infection of immunodeficient mice (BALB/c and other breeds) with *S. Typhimurium*, which causes an illness somewhat similar to human typhoid fever (5). An obvious advantage of these popular models is the avoidance of the cumbersome biosafety constraints involved in work with typhoidal serovars. However, discrepancies between the *S. Typhimurium* model and the *S. Typhi* infection have accumulated in the last decade, and have been comprehensively reviewed recently (6). Differences in genome content, gene regulation and activity of virulence effectors illustrate the limitations of *S. Typhimurium*-based models of typhoid (6). As a consequence, crucial aspects of *S. Typhi* infection remain to be understood, thus limiting the efficacy of diagnostic and therapeutic procedures as well as the development of reliable vaccines.

In a recent study, the early stages of *S. Typhi* infection have been investigated in intestinal biopsies and in organoids derived from human intestinal epithelial tissue (7). Infected biopsies were used to monitor transcriptional changes in the host and the pathogen, to




Figure 1 Differences between *S. Typhimurium* and *S. Typhi* infection illustrate the limitations of the mouse model of typhoid fever. (A) Flagella, very long LPS O-antigen chains and SPI-1 effectors induce an acute immune response in the host upon *S. Typhimurium* infection. Cytokine production results in recruitment of immune cells and migration of neutrophils into the intestinal lumen. This localized inflammatory response helps to contain bacterial dissemination beyond the intestinal submucosa, resulting in self-limiting gastroenteritis. (B) *Salmonella Typhi* evades the host immune response by downregulation of immunogenic surface structures like flagella and T3SS, and by upregulation of the Vi capsule genes. Due to genome degradation, *S. Typhi* does not produce very long O-antigen chains. Absence of immunogenic components reduces recognition by host cell receptors, allowing stealthy crossing of the epithelial barrier and further dissemination.

determine cytokine profiling, and to perform electron microscopy observation. In turn, specific mechanisms were investigated using an organoid model. Unlike traditional epithelial cell cultures growing as monolayers on a plate, organoids mirror the *in vivo* organization of the intestinal epithelium as they develop a three-dimensional architecture (8). Organoids contain the different cell types that constitute the intestinal epithelium (9), which is a major line of defense against microbial pathogens due to the abundance of immune system components (10). Such components are present in organoids and not in epithelial cell cultures.

Active immune evasion by *Salmonella Typhi*

Transcriptomic analysis in biopsy cells infected with *S. Typhi* revealed downregulation of human loci involved in B-cell receptor signaling and in coordination between innate and adaptive immune responses. In contrast, few human genes were found to be upregulated during

infection. Interestingly, comparison of expression patterns in biopsies infected with either *S. Typhi* or *S. Typhimurium* showed stronger downregulation of host genes upon *S. Typhi* infection. Monitoring of MAPK and NF- κ B signaling cascades triggered by bacterial invasion also provided evidence that *S. Typhimurium* elicits a stronger immune response. Cytokine release was detected in supernatants from biopsies infected by *S. Typhi*; however, cytokine genes were not found to be upregulated during infection, suggesting that exposure to *S. Typhi* reduces transcription of cytokine genes. The observation that *S. Typhimurium* elicits a stronger immune response may help to understand the capacity of *S. Typhi* to invade deep tissues, and confirms previous evidence that *S. Typhi* disarms early innate and adaptive immune responses (Figure 1). For instance, the regulatory protein TviA, encoded within the *S. Typhi*-specific pathogenicity island SPI-7, has been shown to attenuate the innate immune response by downregulating bacterial functions that induce the host inflammasome (11-13). Another SPI-7 product, the virulence-associated

(Vi) capsular polysaccharide, appears to prevent complement-mediated phagocytosis (14-16). Active immune evasion during epithelium invasion may thus contribute to 'silent' crossing of the intestinal barrier, permitting stealthy establishment of systemic infection.

Electron microscopy observation indicated that, unlike *S. Typhimurium*, *S. Typhi* invades more frequently enterocytes rather than M cells (7). Microvilli destruction, cell cytoskeleton remodeling and vesicle formation was observed both in biopsy tissues and organoid-derived epithelium monolayers upon *S. Typhi* infection, but cell death was not detected (7). Transcriptomic analysis revealed downregulation of genes involved in cytoskeletal reorganization and in pathways that control formation of cellular protrusions, cytoplasm organization and microtubule dynamics, among others. Altogether, these observations agree with a previous study that compared *S. Typhimurium* and *S. Typhi* interactions with epithelial cells: *S. Typhi* was found to be less adherent, less invasive and less cytotoxic (17).

Distinct gene expression patterns of *Salmonella Typhi* and *Salmonella Typhimurium* during infection

Analysis of *S. Typhi* gene expression patterns during infection of human biopsies showed discrepancies with *S. Typhimurium* (7). For instance, genetic loci required for *S. Typhimurium* invasion like *rpoS*, *ompR* and SPI-1 were found to be downregulated in *S. Typhi*. In contrast, metabolism and ribosomal genes were upregulated during *S. Typhi* invasion. Upregulation of pathogenicity island SPI-7 during biopsy invasion is consistent, as discussed above, with the role of SPI-7 products in immune evasion (7).

Discrepancies in gene expression patterns between *S. Typhi* and *S. Typhimurium* are not surprising: after their evolutionary divergence, each serovar acquired distinct virulence determinants, and *S. Typhi* underwent genome degradation, a distinctive trait of host-restricted serovars (18). Furthermore, differences between *S. Typhi* and *S. Typhimurium* pathogenicity determinants have been previously described. Examples include the structure of the outer core of the LPS (19), the responses to bile (20), and the regulation of flagella and chemotaxis (20).

The model is the message

Animal models are precious tools in translational research if

their predictive value to human disease is high enough (21). In the case of typhoid fever, infection of immunodeficient mice by *Salmonella Typhimurium* has been used for decades to simulate human infection by *S. Typhi*. Aside from permitting the study of *Salmonella* interaction with the animal host without the constraints and the dangers of working with a highly pathogenic species, the mouse model has provided a wealth of information on *Salmonella* virulence mechanisms. However, the steadily growing list of discrepancies between *S. Typhimurium* and *S. Typhi* infection mechanisms illustrates the limitations of the immunodeficient mouse model (6) (Figure 1). In medical practice, the limited efficacy of existing typhoid fever vaccines further illustrates such shortages (22). In this scenario, breakthroughs may require the introduction of novel models like the human biopsy cultures and organoids used in the study discussed in this editorial (7). Organoids may be especially appropriate to study infection, immunity, and inflammation as they provide a source of human tissue that accurately reflects human responses (23).

Acknowledgements

We are grateful to Ángela Mérida-Florianio for critical reading of the manuscript.

Funding: Research in our laboratory is supported by grants PCIN-2015-131 (Infect-ERA) and BIO2016-75235-P from the Spanish Ministerio de Economía y Competitividad (MINECO) and the European Regional Fund.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

1. Brenner FW, Villar RG, Angulo FJ, et al. *Salmonella* nomenclature. *J Clin Microbiol* 2000;38:2465-7.
2. Dougan G, Baker S. *Salmonella enterica* serovar Typhi and the pathogenesis of typhoid fever. *Annu Rev Microbiol* 2014;68:317-36.
3. Gunn JS, Marshall JM, Baker S, et al. *Salmonella* chronic carriage: Epidemiology, diagnosis, and gallbladder persistence. *Trends Microbiol* 2014;22:648-55.
4. Urdaneta V, Casadesús J. Interactions between bacteria and bile salts in the gastrointestinal and hepatobiliary tracts. *Front Med (Lausanne)* 2017;4:163.

5. Tsolis RM, Xavier MN, Santos RL, et al. How to become a top model: Impact of animal experimentation on human *Salmonella* disease research. *Infect Immun* 2011;79:1806-14.
6. Johnson R, Mylona E, Frankel G. Typhoidal *Salmonella*: distinctive virulence factors and pathogenesis. *Cell Microbiol* 2018;20:e12939.
7. Nickerson KP, Senger S, Zhang Y, et al. *Salmonella* Typhi colonization provokes extensive transcriptional changes aimed at evading host mucosal immune defense during early infection of human intestinal tissue. *EBioMedicine* 2018;31:92-109.
8. Wilson SS, Tocchi A, Holly MK, et al. A small intestinal organoid model of non-invasive enteric pathogen-epithelial cell interactions. *Mucosal Immunol* 2015;8:352-61.
9. Forbester JL, Goulding D, Vallier L, et al. Interaction of *Salmonella enterica* serovar Typhimurium with intestinal organoids derived from human induced pluripotent stem cells. *Infect Immun* 2015;83:2926-34.
10. Langerholc T, Maragkoudakis PA, Wollgast J, et al. Novel and established intestinal cell line models - An indispensable tool in food science and nutrition. *Trends Food Sci Technol* 2011;22:S11-20.
11. Winter SE, Winter MG, Poon V, et al. *Salmonella enterica* serovar Typhi conceals the invasion-associated type three secretion system from the innate immune system by gene regulation. *PLoS Pathog* 2014;10:e1004207.
12. Winter SE, Raffatellu M, Wilson PR, et al. The *Salmonella enterica* serotype Typhi regulator TviA reduces interleukin-8 production in intestinal epithelial cells by repressing flagellin secretion. *Cell Microbiol* 2008;10:247-61.
13. Winter SE, Winter MG, Atluri V, et al. The flagellar regulator TviA reduces pyroptosis by *Salmonella enterica* serovar Typhi. *Infect Immun* 2015;83:1546-55.
14. Wilson RP, Winter SE, Spees AM, et al. The Vi capsular polysaccharide prevents complement receptor 3-mediated clearance of *Salmonella enterica* serotype Typhi. *Infect Immun* 2011;79:830-7.
15. Crawford RW, Wangdi T, Spees AM, et al. Loss of very-long O-antigen chains optimizes capsule-mediated immune evasion by *Salmonella enterica* serovar Typhi. *MBio* 2013;4:1-8.
16. Wangdi T, Lee CY, Spees AM, et al. The Vi capsular polysaccharide enables *Salmonella enterica* serovar Typhi to evade microbe-guided neutrophil chemotaxis. *PLoS Pathog* 2014;10:e1004306.
17. Bishop A, House D, Perkins T, et al. Interaction of *Salmonella enterica* serovar Typhi with cultured epithelial cells: Roles of surface structures in adhesion and invasion. *Microbiology* 2008;154:1914-26.
18. Barquist L, Langridge GC, Turner DJ, et al. A comparison of dense transposon insertion libraries in the *Salmonella* serovars Typhi and Typhimurium. *Nucleic Acids Res* 2013;41:4549-64.
19. Bravo D, Hoare A, Silipo A, et al. Different sugar residues of the lipopolysaccharide outer core are required for early interactions of *Salmonella enterica* serovars Typhi and Typhimurium with epithelial cells. *Microb Pathog* 2011;50:70-80.
20. Johnson R, Ravenhall M, Pickard D, et al. Comparison of *Salmonella enterica* serovars Typhi and Typhimurium reveals typhoidal serovar-specific responses to bile. *Infect Immun* 2018;86:1-16.
21. Denayer T, Stöhrn T, Van Roy M. Animal models in translational medicine: Validation and prediction. *New Horizons Transl Med* 2014;2:5-11.
22. Higginson EE, Simon R, Tennant SM. Animal models for salmonellosis: Applications in vaccine research. *Clin Vaccine Immunol* 2016;23:746-56.
23. Iakobachvili N, Peters PJ. Humans in a dish: The potential of organoids in modeling immunity and infectious diseases. *Front Microbiol* 2017;8:2402.

Cite this article as: Urdaneta V, Casadesús J. Host-pathogen interactions in typhoid fever: the model is the message. *Ann Transl Med* 2018;6(Suppl 1):S38. doi: 10.21037/atm.2018.09.52